The LocoMMotion study, a multinational prospective observational trial, examined the effectiveness and safety of real-world clinical practice treatments in triple-class exposed patients with multiple myeloma who had received proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies. Results highlighted a lack of standard-of-care therapies and poor outcomes, with a median progression-free survival of 4.6 months and an overall survival of 13.8 months. Of 91 unique treatment regimens observed, only 31.9% of patients achieved an objective response, and responses were neither deep nor durable. Hematologic adverse events were common, and 63.7% of patients died, primarily due to progressive disease.

The study underscores the pressing need for more effective and standardized treatment options for this patient population. While subgroup analyses revealed that patients achieving very good partial response or better had improved outcomes, achieving this depth of response was rare. LocoMMotion provides valuable insights into the challenges of treating triple-class exposed patients with MM and serves as a benchmark for evaluating novel therapies that hold promise for improving outcomes in this difficult-to-treat population.

Reference: Mateos MV, Weisel K, De Stefano V, et al. LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma – 2-year follow-up (final analysis). Leukemia. 2024;38(12):2554-2560. doi:10.1038/s41375-024-02404-6